Personalis, Inc. Announces New Data to be Presented at ASCO Virtual Scientific Meeting
One abstract showcases data from the ImmunoID NeXT Platform™, the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. ImmunoID NeXT can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a precious tumor specimen.
Another abstract highlights data from the Personalis NeXT Dx™ Test, one of the first cancer diagnostic platforms to profile approximately 20,000 genes in both the tumor exome and transcriptome, providing a comprehensive genomic testing solution that goes beyond many existing cancer diagnostic panels that focus on a few hundred genes. The Personalis NeXT Dx Test includes advanced analytics to provide a diagnostic report on genetic alterations in clinically-important cancer genes, as well as emerging immunotherapy composite biomarkers of medical importance.
Following are details and links to the abstracts that will be presented at the online meeting.
Abstract Number & |
Title & Presenter |
Date |
Location |
|||
6557 |
Exome scale liquid biopsy characterization of putative neoantigens and genomic biomarkers pre- and post anti-PD-1 therapy in squamous cell carcinoma of the head and neck. |
|
||||
e15583 |
Validation of an exome and transcriptome based diagnostic platform enabling clinical cancer therapy selection and emerging composite biomarkers for immunotherapy. |
|
About
Forward-Looking Statements
This press release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, forward-looking statements include statements regarding the future availability, features or potential uses of the ImmunoID NeXT Platform or NeXT Dx Test and other future events. These forward-looking statements are subject to risks and uncertainties, including those related to the evolution of cancer therapies and market adoption of our services, our expectations regarding future performance, and the COVID-19 pandemic, as well as other risks and uncertainties discussed in Personalis’ filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20200529005485/en/
Investor Relations Contact for
investors@personalis.com
415-202-5678
Media Contact for
pr@personalis.com
www.personalis.com
650-752-1300
Source: